annual cash & cash equivalents:
$11.97B+$1.03B(+9.40%)Summary
- As of today (May 23, 2025), AMGN annual cash & cash equivalents is $11.97 billion, with the most recent change of +$1.03 billion (+9.40%) on December 31, 2024.
- During the last 3 years, AMGN annual cash & cash equivalents has risen by +$3.98 billion (+49.87%).
- AMGN annual cash & cash equivalents is now at all-time high.
Performance
AMGN Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$8.81B-$3.16B(-26.42%)Summary
- As of today (May 23, 2025), AMGN quarterly cash & cash equivalents is $8.81 billion, with the most recent change of -$3.16 billion (-26.42%) on March 31, 2025.
- Over the past year, AMGN quarterly cash & cash equivalents has dropped by -$898.00 million (-9.25%).
- AMGN quarterly cash & cash equivalents is now -74.64% below its all-time high of $34.74 billion, reached on September 30, 2023.
Performance
AMGN quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AMGN Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +9.4% | -9.3% |
| 3 y3 years | +49.9% | +35.0% |
| 5 y5 years | +98.3% | +14.6% |
AMGN Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +56.9% | -74.6% | +69.3% |
| 5 y | 5-year | at high | +98.3% | -74.6% | +69.3% |
| alltime | all time | at high | >+9999.0% | -74.6% | >+9999.0% |
AMGN Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $8.81B(-26.4%) |
| Dec 2024 | $11.97B(+9.4%) | $11.97B(+32.9%) |
| Sep 2024 | - | $9.01B(-3.1%) |
| Jun 2024 | - | $9.30B(-4.2%) |
| Mar 2024 | - | $9.71B(-11.3%) |
| Dec 2023 | $10.94B(+43.5%) | $10.94B(-68.5%) |
| Sep 2023 | - | $34.74B(+1.4%) |
| Jun 2023 | - | $34.25B(+8.5%) |
| Mar 2023 | - | $31.56B(+313.7%) |
| Dec 2022 | $7.63B(-4.5%) | $7.63B(-19.7%) |
| Sep 2022 | - | $9.50B(+82.6%) |
| Jun 2022 | - | $5.20B(-20.3%) |
| Mar 2022 | - | $6.53B(-18.3%) |
| Dec 2021 | $7.99B(+27.5%) | $7.99B(-33.3%) |
| Sep 2021 | - | $11.97B(+80.5%) |
| Jun 2021 | - | $6.63B(+8.5%) |
| Mar 2021 | - | $6.11B(-2.5%) |
| Dec 2020 | $6.27B(+3.8%) | $6.27B(-31.0%) |
| Sep 2020 | - | $9.09B(-0.6%) |
| Jun 2020 | - | $9.14B(+19.0%) |
| Mar 2020 | - | $7.69B(+27.3%) |
| Dec 2019 | $6.04B(-13.1%) | $6.04B(-47.1%) |
| Sep 2019 | - | $11.41B(+106.6%) |
| Jun 2019 | - | $5.53B(-24.9%) |
| Mar 2019 | - | $7.36B(+5.9%) |
| Dec 2018 | $6.95B(+82.8%) | $6.95B(-41.9%) |
| Sep 2018 | - | $11.96B(+18.0%) |
| Jun 2018 | - | $10.13B(+4.0%) |
| Mar 2018 | - | $9.74B(+156.3%) |
| Dec 2017 | $3.80B(+17.2%) | $3.80B(+26.7%) |
| Sep 2017 | - | $3.00B(+14.1%) |
| Jun 2017 | - | $2.63B(-21.7%) |
| Mar 2017 | - | $3.36B(+3.6%) |
| Dec 2016 | $3.24B(-21.8%) | $3.24B(-7.0%) |
| Sep 2016 | - | $3.48B(+32.5%) |
| Jun 2016 | - | $2.63B(-9.2%) |
| Mar 2016 | - | $2.90B(-30.1%) |
| Dec 2015 | $4.14B(+11.1%) | $4.14B(+28.5%) |
| Sep 2015 | - | $3.23B(-15.0%) |
| Jun 2015 | - | $3.79B(+32.5%) |
| Mar 2015 | - | $2.86B(-23.2%) |
| Dec 2014 | $3.73B(-1.9%) | $3.73B(+1.5%) |
| Sep 2014 | - | $3.68B(-15.5%) |
| Jun 2014 | - | $4.35B(+18.0%) |
| Mar 2014 | - | $3.69B(-3.1%) |
| Dec 2013 | $3.81B(+16.8%) | $3.81B(-54.1%) |
| Sep 2013 | - | $8.28B(+42.6%) |
| Jun 2013 | - | $5.81B(+129.5%) |
| Mar 2013 | - | $2.53B(-22.3%) |
| Dec 2012 | $3.26B(-53.1%) | $3.26B(-44.1%) |
| Sep 2012 | - | $5.82B(-0.4%) |
| Jun 2012 | - | $5.85B(+39.0%) |
| Mar 2012 | - | $4.21B(-39.4%) |
| Dec 2011 | $6.95B(+111.3%) | $6.95B(+78.5%) |
| Sep 2011 | - | $3.89B(-35.1%) |
| Jun 2011 | - | $6.00B(+373.8%) |
| Mar 2011 | - | $1.27B(-61.5%) |
| Dec 2010 | $3.29B(+14.0%) | $3.29B(+92.0%) |
| Jun 2010 | - | $1.71B(-24.4%) |
| Mar 2010 | - | $2.27B(-21.4%) |
| Dec 2009 | $2.88B(+62.6%) | $2.88B(-19.4%) |
| Sep 2009 | - | $3.58B(+20.5%) |
| Jun 2009 | - | $2.97B(+6.9%) |
| Mar 2009 | - | $2.78B(+56.5%) |
| Dec 2008 | $1.77B(-12.4%) | $1.77B(-29.7%) |
| Sep 2008 | - | $2.52B(-25.6%) |
| Jun 2008 | - | $3.39B(-21.6%) |
| Mar 2008 | - | $4.32B(+113.6%) |
| Dec 2007 | $2.02B(+57.8%) | $2.02B(+45.7%) |
| Sep 2007 | - | $1.39B(-19.6%) |
| Jun 2007 | - | $1.73B(+61.9%) |
| Mar 2007 | - | $1.07B(-16.8%) |
| Dec 2006 | $1.28B | $1.28B(-0.6%) |
| Sep 2006 | - | $1.29B(-33.7%) |
| Jun 2006 | - | $1.95B(+11.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2006 | - | $1.75B(-5.1%) |
| Dec 2005 | $1.84B(+20.6%) | $1.84B(-14.5%) |
| Sep 2005 | - | $2.15B(+32.7%) |
| Jun 2005 | - | $1.62B(+37.0%) |
| Mar 2005 | - | $1.18B(-22.5%) |
| Dec 2004 | $1.53B(+82.3%) | $1.53B(+54.8%) |
| Sep 2004 | - | $986.00M(-42.6%) |
| Jun 2004 | - | $1.72B(+125.5%) |
| Mar 2004 | - | $761.50M(-9.0%) |
| Dec 2003 | $837.00M(-54.8%) | $837.00M(-20.3%) |
| Sep 2003 | - | $1.05B(-1.9%) |
| Jun 2003 | - | $1.07B(-54.3%) |
| Mar 2003 | - | $2.34B(+26.4%) |
| Dec 2002 | $1.85B(+168.8%) | $1.85B(+59.8%) |
| Sep 2002 | - | $1.16B(-60.1%) |
| Jun 2002 | - | $2.90B(-2.6%) |
| Mar 2002 | - | $2.98B(+332.6%) |
| Dec 2001 | $689.10M(+204.2%) | $689.10M(+142.6%) |
| Sep 2001 | - | $284.00M(+0.5%) |
| Jun 2001 | - | $282.50M(-41.0%) |
| Mar 2001 | - | $478.90M(+111.4%) |
| Dec 2000 | $226.50M(+73.0%) | $226.50M(+41.7%) |
| Sep 2000 | - | $159.80M(+17.3%) |
| Jun 2000 | - | $136.20M(+8.3%) |
| Mar 2000 | - | $125.80M(-3.9%) |
| Dec 1999 | $130.90M(-34.9%) | $130.90M(-30.5%) |
| Sep 1999 | - | $188.30M(-5.7%) |
| Jun 1999 | - | $199.60M(+74.9%) |
| Mar 1999 | - | $114.10M(-43.3%) |
| Dec 1998 | $201.10M(-15.9%) | $201.10M(+93.2%) |
| Sep 1998 | - | $104.10M(-34.1%) |
| Jun 1998 | - | $158.00M(+51.1%) |
| Mar 1998 | - | $104.60M(-56.3%) |
| Dec 1997 | $239.10M(+41.2%) | $239.10M(-0.3%) |
| Sep 1997 | - | $239.90M(-27.5%) |
| Jun 1997 | - | $331.00M(+25.0%) |
| Mar 1997 | - | $264.80M(+56.4%) |
| Dec 1996 | $169.30M(+153.8%) | $169.30M(-25.4%) |
| Sep 1996 | - | $227.00M(+6.0%) |
| Jun 1996 | - | $214.20M(+243.3%) |
| Mar 1996 | - | $62.40M(-6.4%) |
| Dec 1995 | $66.70M(-68.4%) | $66.70M(-54.0%) |
| Sep 1995 | - | $145.00M(-25.6%) |
| Jun 1995 | - | $194.90M(-2.1%) |
| Mar 1995 | - | $199.00M(-5.8%) |
| Dec 1994 | $211.30M(+64.4%) | $211.30M(-29.9%) |
| Sep 1994 | - | $301.50M(+19.8%) |
| Jun 1994 | - | $251.60M(+70.3%) |
| Mar 1994 | - | $147.70M(+14.9%) |
| Dec 1993 | $128.50M(+39.7%) | $128.50M(-21.2%) |
| Sep 1993 | - | $163.00M(+19.6%) |
| Jun 1993 | - | $136.30M(+519.5%) |
| Mar 1993 | - | $22.00M(-76.1%) |
| Dec 1992 | $92.00M(-37.2%) | $92.00M(+43.8%) |
| Sep 1992 | - | $64.00M(-12.1%) |
| Jun 1992 | - | $72.80M(-48.0%) |
| Mar 1992 | - | $140.10M(-4.4%) |
| Dec 1991 | $146.50M(+310.4%) | $146.50M(+36.8%) |
| Sep 1991 | - | $107.10M(+37.8%) |
| Jun 1991 | - | $77.70M(+117.6%) |
| Mar 1991 | - | $35.70M(-35.3%) |
| Mar 1991 | $35.70M(-8.9%) | - |
| Dec 1990 | - | $55.20M(+30.5%) |
| Sep 1990 | - | $42.30M(-48.2%) |
| Jun 1990 | - | $81.70M(+108.4%) |
| Mar 1990 | $39.20M(+89.4%) | $39.20M(+69.0%) |
| Dec 1989 | - | $23.20M(+75.8%) |
| Sep 1989 | - | $13.20M(-82.8%) |
| Jun 1989 | - | $76.80M(+271.0%) |
| Mar 1989 | $20.70M(-80.4%) | $20.70M(-80.4%) |
| Mar 1988 | $105.60M(+83.3%) | $105.60M(+83.3%) |
| Mar 1987 | $57.60M(-13.5%) | $57.60M(-13.5%) |
| Mar 1986 | $66.60M(+198.7%) | $66.60M(+198.7%) |
| Mar 1985 | $22.30M(-40.7%) | $22.30M(-40.7%) |
| Mar 1984 | $37.60M | $37.60M |
FAQ
- What is Amgen annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Amgen?
- What is Amgen annual cash & cash equivalents year-on-year change?
- What is Amgen quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Amgen?
- What is Amgen quarterly cash & cash equivalents year-on-year change?
What is Amgen annual cash & cash equivalents?
The current annual cash & cash equivalents of AMGN is $11.97B
What is the all time high annual cash & cash equivalents for Amgen?
Amgen all-time high annual cash & cash equivalents is $11.97B
What is Amgen annual cash & cash equivalents year-on-year change?
Over the past year, AMGN annual cash & cash equivalents has changed by +$1.03B (+9.40%)
What is Amgen quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of AMGN is $8.81B
What is the all time high quarterly cash & cash equivalents for Amgen?
Amgen all-time high quarterly cash & cash equivalents is $34.74B
What is Amgen quarterly cash & cash equivalents year-on-year change?
Over the past year, AMGN quarterly cash & cash equivalents has changed by -$898.00M (-9.25%)